The Pharmaceutical Journal
Vol 272 No 7299 p597
15 May 2004

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Two more medicines advertisements blocked by regulator

Promotional material for two anti-hypertensive agents has been withdrawn after complaints to the Medicines and Healthcare products Regulatory Agency.

The complaints were made in March, shortly before the MHRA issued advice to companies not to make claims that imply that medicines have no side effects when their summaries of product characteristics made clear that they do. Both advertisements, for Aprovel (irbesartan, Sanofi-Synthelabo and Bristol Myers Squibb Ltd) and Amias (candesartan, Takeda UK Ltd and AstraZeneca UK Ltd), claimed “placebo-like tolerability”.